Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Arch Toxicol ; 95(1): 345-353, 2021 01.
Artículo en Inglés | MEDLINE | ID: mdl-32880718

RESUMEN

Snakebite envenomation causes > 81,000 deaths and incapacities in another 400,000 people worldwide every year. Snake venoms are complex natural secretions comprised of hundreds of different molecules with a wide range of biological functions that after injection cause local and systemic manifestations. Although several studies have investigated snake venoms, the majority have focused on the protein portion (toxins), without significant attention paid to the lipid fraction. Therefore, an untargeted lipidomic approach based on liquid chromatography with high-resolution mass spectrometry (LC-HRMS) was applied to investigate the lipid constituents of venoms of the snake species Crotalus durissus terrificus and Bothrops moojeni. Phosphatidylcholines (PC), Lyso-PCs, phosphatidylethanolamines (PE), Lyso-PE, phosphatidylserine (PS), phosphatidylinositol (PI), ceramides (Cer), and sphingomyelin (SM) species were detected in the analyzed snake venoms. The identified lipids included bioactive compounds such as platelet-activating factor (PAF) precursor, PAF-like molecules, plasmalogens, ceramides, and sphingomyelins with long fatty acid chain lengths, which may be associated with the systemic responses triggered by C. d. terrificus and B. moojeni envenomation. These responses include platelet aggregation, activation of intercellular adhesion molecule 1 (ICAM1), apoptosis, as well as the production of pro-inflammatory lipid mediators, cytokines, and reactive species. The newly proposed lipidomics strategy provided valuable information regarding the lipid profiles of viperid venoms, which could lead to increased understanding of the complex pathology promoted by snakebite envenomation.


Asunto(s)
Bothrops , Ceramidas/metabolismo , Venenos de Crotálidos/metabolismo , Crotalus , Lipidómica , Fosfolípidos/metabolismo , Mordeduras de Serpientes , Esfingomielinas/metabolismo , Animales , Ceramidas/toxicidad , Cromatografía Líquida de Alta Presión , Venenos de Crotálidos/toxicidad , Fosfolípidos/toxicidad , Esfingomielinas/toxicidad , Espectrometría de Masas en Tándem
2.
Regul Toxicol Pharmacol ; 100: 59-67, 2018 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-30359697

RESUMEN

Fx-5A peptide complex (Fx-5A), a High Density Lipoproteins (HDL) mimetic, has been shown to reduce atherosclerosis. The safety and toxicokinetics of Fx-5A administered IV by 30 min infusion at 8, 25 or 75 mg/kg body weight or vehicle, once every other day for 27 days, were assessed in cynomolgus monkeys. The Fx-5A was well tolerated at all doses. At the highest dose, there were statistically significant effects on hematology and clinical chemistry parameters that were considered non-adverse. Dose-dependent recoverable non-adverse erythrocytes morphological changes (acanthocytes, echinocytes, spherocytes, microcytes, and/or schistocytes) were observed. Fx-5A was not hemolytic in in-vitro fresh NHP or human blood assay. There were no Fx-5A-related statistically significant changes for any cardiovascular function, ECG or respiratory parameters, when compared to control. In addition, there were no Fx-5A-related effects on organ weights, macroscopic or microscopic endpoints. Finally, Fx-5A exhibited sporadic non-appreciable detection of anti-Fx-5A antibodies and a dose-dependent linear toxicokinetics with T1/2 value ranges from 2.7 to 6.2 h. In conclusion, the No Observed Adverse Effect Level was considered to be 75 mg/kg/day with associated exposures average Cmax and AUC0-last of 453 µg/mL and 2232 h µg/mL, respectively, on Day 27.


Asunto(s)
Péptidos/farmacocinética , Péptidos/toxicidad , Esfingomielinas/farmacocinética , Esfingomielinas/toxicidad , Administración Intravenosa , Animales , Femenino , Péptidos y Proteínas de Señalización Intercelular , Lipoproteínas HDL , Macaca fascicularis , Masculino , Nivel sin Efectos Adversos Observados , Péptidos/sangre
3.
EMBO Mol Med ; 6(3): 398-413, 2014 03.
Artículo en Inglés | MEDLINE | ID: mdl-24448491

RESUMEN

Understanding the role of lipids in synapses and the aberrant molecular mechanisms causing the cognitive deficits that characterize most lipidosis is necessary to develop therapies for these diseases. Here we describe sphingomyelin (SM) as a key modulator of the dendritic spine actin cytoskeleton. We show that increased SM levels in neurons of acid sphingomyelinase knock out mice (ASMko), which mimic Niemann Pick disease type A (NPA), result in reduced spine number and size and low levels of filamentous actin. Mechanistically, SM accumulation decreases the levels of metabotropic glutamate receptors type I (mGluR1/5) at the synaptic membrane impairing membrane attachment and activity of RhoA and its effectors ROCK and ProfilinIIa. Pharmacological enhancement of the neutral sphingomyelinase rescues the aberrant molecular and morphological phenotypes in vitro and in vivo and improves motor and memory deficits in ASMko mice. Altogether, these data demonstrate the influence of SM and its catabolic enzymes in dendritic spine physiology and contribute to our understanding of the cognitive deficits of NPA patients, opening new perspectives for therapeutic interventions.


Asunto(s)
Espinas Dendríticas/efectos de los fármacos , Enfermedad de Niemann-Pick Tipo A/tratamiento farmacológico , Enfermedad de Niemann-Pick Tipo A/patología , Citoesqueleto de Actina/efectos de los fármacos , Animales , Apoptosis/efectos de los fármacos , Células Cultivadas , Espinas Dendríticas/metabolismo , Dexametasona/farmacología , Modelos Animales de Enfermedad , Femenino , Memoria a Corto Plazo/efectos de los fármacos , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Actividad Motora/efectos de los fármacos , Neuronas/citología , Neuronas/efectos de los fármacos , Neuronas/metabolismo , Enfermedad de Niemann-Pick Tipo A/metabolismo , Esfingomielina Fosfodiesterasa/deficiencia , Esfingomielina Fosfodiesterasa/genética , Esfingomielina Fosfodiesterasa/metabolismo , Esfingomielinas/toxicidad
4.
Toxicon ; 27(5): 531-40, 1989.
Artículo en Inglés | MEDLINE | ID: mdl-2501911

RESUMEN

A cytotoxic protein isolated from Pseudomonas aeruginosa damages the plasma membranes of many mammalian cells by forming pores. We studied binding of the 125I-cytotoxin and the resulting increase of cation permeability in erythrocytes of various mammalian species. The sensitivity of red blood cells was inversely related to the relative sphingomyelin content in their external surface. Thus, erythrocytes with a sphingomyelin to phosphatidylcholine ratio below 1 (dog, rat, rabbit and man) were sensitive, whereas red blood cells with a ratio above 1 (pig, cattle and sheep) were not attacked even with 100-fold higher cytotoxin concentrations. At 37 degrees C 6.8 +/- 1.2 x 10(3) molecules of 125I-cytotoxin were bound per rabbit erythrocyte (KD = 59 nM), whereas no binding occurred to cattle cells. Cleavage of sphingomyelin by sphingomyelinase C from Bacillus cereus (EC 3.1.4.12) triggered a dose-dependent enhancement in binding and permeability increase, particularly in red blood cells with a high proportion of sphingomyelin. The KDs for all animal species investigated were 53-60 nM. Pretreatment with mainly phosphatidylcholine-hydrolyzing phospholipases D from Streptomyces chromofuscus and cabbage (EC 3.1.4.4) or phospholipase C from Bacillus cereus (EC 3.1.4.3) did not influence the cytotoxin effect. The negative correlation between susceptibility and the proportion of sphingomyelin in plasma membranes suggests a binding site close to sphingomyelin.


Asunto(s)
Citotoxinas/toxicidad , Membrana Eritrocítica/efectos de los fármacos , Pseudomonas aeruginosa/metabolismo , Esfingomielinas/toxicidad , Animales , Sitios de Unión , Cationes/metabolismo , Bovinos , Citotoxinas/metabolismo , Perros , Humanos , Fosfolipasas/farmacología , Conejos , Ratas , Ovinos , Especificidad de la Especie , Esfingomielinas/metabolismo , Porcinos
5.
Br J Exp Pathol ; 64(6): 670-6, 1983 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-6419767

RESUMEN

Chronic treatment (10 i.p. injections over 20 days) of Balb/c mice with SM liposomes led to 50 and 300% enlargement of the liver and spleen respectively. No such effect was observed after similar treatment with PC liposomes. Biochemical analysis of the enlarged tissues showed no significant changes in the concentrations of glycolipid, phospholipid and certain hydrolytic enzymes. However, the increase in tissue size was paralleled by an increase in protein content. Light and electron microscopy studies of the enlarged tissues revealed an increase in the number of Kupffer cells and collections of inflammatory cells in the liver and widespread granulomatous inflammation in the spleen. We conclude that SM liposomes, although probably toxic for use as a drug carrier, may serve as a model agent in the study of tissue granulomatous inflammation.


Asunto(s)
Hepatomegalia/inducido químicamente , Esfingomielinas/toxicidad , Esplenomegalia/inducido químicamente , Animales , Glucosilceramidas/metabolismo , Granuloma/patología , Hepatomegalia/patología , Liposomas/administración & dosificación , Hígado/enzimología , Hígado/ultraestructura , Ratones , Ratones Endogámicos BALB C , Microscopía Electrónica , Tamaño de los Órganos , Fosfatidilcolinas/toxicidad , Bazo/ultraestructura , Esplenomegalia/patología , beta-Glucosidasa/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA